Scope Fluidics S.A.
Other research and experimental development on natural sciences and engineering
Overview
Scope Fluidics is a biotechnology company that develops microfluidic technologies for medical diagnostics and healthcare. It owns Bacteromic, established to develop a system for assessing microorganisms’ drug susceptibility, and developed PCR|ONE for rapid diagnosis of bacterial and viral diseases through Curiosity Diagnostics, whose shares were acquired by Bio-Rad in 2022.
Financials
Revenue history (in k)
Filing timeliness
Financial statements were filed on time, on average 41 days early. All were audited by a statutory auditor.
- 202513/07/2026
- 202427/06/2025
- 202328/06/2024
- 202203/04/2023
- 202107/07/2022
- 202007/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 145.20
- High
- PLN 148.00
- Low
- PLN 140.80
- Volume
- 4.44K
- Avg. vol.
- 2.02K
- Market cap
- PLN 449.89M
- P/E ratio
- –
- EPS
- -PLN 15.91
- Shares outstanding
- 3.17M
- 52-week
- PLN 137.00 – 148.00
- Dividend yield
- 60.26%
- Dividend
- PLN 85.57
- Ex dividend date
- Mar 24, 2023
- ISIN
- PLSCPFL00018
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD -0.04 | USD -1.46k | USD 26.95 |
| Q1 2026 | USD 0.01 | USD -1.30k | USD 25.65 |
| Q4 2025 | USD 0.01 | USD -7.25k | USD 25.25 |
| Q3 2025 | USD 0.07 | USD -5.94k | USD -39.56 |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

Scope Fluidics Secures Another U.S. Patent for the BACTEROMIC System

Scope Fluidics signs agreement for distribution of the BACTEROMIC system in 10 European markets

Scope Fluidics Signs Agreement for Clinical Trials of the BACTEROMIC System PBC Panel
Scope Fluidics Signs Agreement for Clinical Trials of the BACTEROMIC System PBC Panel

Scope Fluidics Secures New Location for Semi-Automated BACTEROMIC Panel Production Line
Scope Fluidics Secures New Location for Semi-Automated BACTEROMIC Panel Production Line
Industry
Offer
- Medical diagnostic systems
- PCR|ONE system
- BACTEROMIC system
- Microfluidic research
- Diagnostic device development
- Clinical trials
Websites
The site is available in: Polish and English.
- scopefluidics.comScope Fluidics – SCOPE FLUIDICSWordPress 3.7ElementorGoogle AnalyticsGoogle Tag ManagerYoast SEOWWPMLLLiteSpeed
Trademarks
The company holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2012.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| Scope Fluidics (word) | Z.561737 | 10, 35, 36, 41, 42, 45 | Protected | Oct 19, 2033 | |
| SCOPE fluidics | Z.402736 | 5, 10, 42 | Protected | Jul 10, 2032 |
| Mark | Protected until | |
|---|---|---|
| Scope Fluidics (word) | Oct 19, 2033 | |
| SCOPE fluidics | Jul 10, 2032 |
Job offers
The company has its own careers page: scopefluidics.com/career-scope-fluidics.
Authorized Representatives
Manner of representation
The company is represented by two members of the management board acting jointly, or one member of the management board together with a commercial proxy.
Supervisory board
Beneficial owners
Scope Fluidics is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Bacteromic sp. z o.o. | 10,293,084.82 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
| 71% |
Bank accounts
Registered as a VAT taxpayer on 2011-01-31.
11 2490 0005 0000 4600 1874 5090
19 1600 1462 1740 9438 7000 0001
03 2490 0005 0000 4520 3046 2136
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $22,557.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,184$4,184 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,472$4,472 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,644$3,644 | Prezes Zakładu Ubezpieczeń Społecznych |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Centrum Innowacji I Wdrożeń Bio-Inwest sp. z o.o. | $1,262,872.91 | bio-inwest.pl | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Nanogroup S.A. | $843,099.47 | nanogroup.eu | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl | ||
| BIO-Chic sp. z o.o. | $663,672.32 | bio-chic.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-26 | Share capital increase (272,593.00 PLN → 316,827.10 PLN) | |
| 2023-01-26 | Address change (Ul. Duchnicka 3, Bud.16/Wejście A, 01-796, Warszawa → Ul. Ogrodowa 58, 00-876, Warszawa) | |
| 2022-11-15 | Share capital increase (268,620.50 PLN → 272,593.00 PLN) | |
| 2020-11-30 | Share capital increase (255,829.00 PLN → 268,620.50 PLN) | |
| 2020-04-07 | Share capital increase (254,694.00 PLN → 255,829.00 PLN) |
FAQ
Last updated: 2026-07-16